



11 October 2021

ASX Announcement

Updated Investor Presentation

MELBOURNE Australia, 11 October 2021: Australian mid-clinical stage antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA) is pleased to share its latest investor presentation.

In the coming week Island Pharmaceuticals management team will be participating in a non-deal roadshow in the US providing an update on the Company's progress. The presentation materials are attached.

Approved for release to the ASX by:

Dr Paul MacLeman
 Executive Chairman
 Isla Pharmaceuticals
info@islandpharmaceuticals.com

For further information, please contact:

<p>Investors: Jane Lowe IR Department Mobile: +61 411 117 774 jane.lowe@irdepartment.com.au</p>	<p>Media: Juliana Roadley IR Department Mobile: +61 414 889 863 juliana.roadley@irdepartment.com.au</p>
---	---

About Island Pharmaceuticals

Island is clinical-stage drug repurposing company, focused on the topical area of antiviral therapeutics for infectious diseases. Our lead asset is ISLA-101, a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. The Company is advancing toward a Phase II clinical trial in dengue-infected subjects.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Isla may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) would permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.